Product Description: Calhex 231 hydrochloride is a potent negative allosteric modulator that blocks (IC50 = 0.39 μM) increases in [3H]inositol phosphates elicited by activating the human wild-type CaSR transiently Ca2+-sensing receptor. Calhex 231 hydrochloride can be used in the study of traumatic hemorrhagic shock (THS) and diabetic cardiomyopathy (DCM)[1].
Applications: Metabolism-sugar/lipid metabolism
Formula: C25H28Cl2N2O
Citations: Food Chem. 2024 Jul 6:459:140359./Front Pharmacol. 2022 Feb 23;13:816133./Front Pharmacol. 23 February 2022./Mol Nutr Food Res. 2023 Dec 31:e2200726./Eur J Pharmacol. 2024 Jul 31:980:176828.
References: [1]Christophe Petrel, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94./[2]Petrel C1, et al. Modeling and mutagenesis of the binding site of Calhex 231, a novel negative allosteric modulator of the extracellular Ca(2+)-sensing receptor. J Biol Chem. 2003 Dec 5;278(49):49487-94./[3]Yan Lei, et al. The Calcilytic Drug Calhex-231 Ameliorates Vascular Hyporesponsiveness in Traumatic Hemorrhagic Shock by Inhibiting Oxidative Stress and miR-208a-Mediated Mitochondrial Fission. Oxid Med Cell Longev. 2020 Dec 3:2020:4132785.
CAS Number: 2387505-78-2
Molecular Weight: 443.41
Compound Purity: 99.81
Research Area: Metabolic Disease
Solubility: DMSO : 33.33 mg/mL (ultrasonic)
Target: CaSR
Deutsch
English
